

The Chemours Company Class Action Lawsuit

U.S. Securities Litigation

Chemours Class Action Lawsuit Allegations

The Chemours class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned *Darcy v. The Chemours Company*, No. 26-cv-1299.

If you lost money on your Chemours investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is Chemours Being Sued for Securities Fraud?

Chemours has been sued for securities fraud following a significant stock drop resulting from alleged violations of the federal securities laws. The decline in Chemours's stock price caused significant losses to investors.

Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.

According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of \$800M – \$900M, driven by "higher . . . demand" in its Opteon segment.

As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an “oversupplied channel heading into 2026.”

Why did Chemours’s Stock Drop?

On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to \$775M – \$825M from \$800M – \$900M). Chemours also revealed that customers had “built additional inventory” of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an “oversupplied channel heading into 2026.”

On this news, Chemours’s stock dropped \$3.34 per share, or 18.63%, from a closing price of \$17.93 per share on August 4, 2026, to \$14.59 per share on August 5, 2026.

Chemours (\$CC) Stock Chart



Image Caption: NYSE online chart showing the Chemours (CC) stock drop following the August 2026 disclosure.

What is the Chemours Lead Plaintiff Deadline?

You may ask the Court no later than December 7, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information?

If you lost money when Chemours securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall

amccall@bfalaw.com

212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*.

BFA attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, “Litigation Stars” by *Benchmark Litigation*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360*, and “SuperLawyers” by *Thomson Reuters*.

Most recently, *The Legal 500* awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over \$900 million in value from Tesla, Inc.’s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.

